Keyuan Pharmaceutical announced that its wholly-owned subsidiary Shandong Linuo Pharmaceutical Co., Ltd. added 4 new products to the “National Essential Drug Catalogue”. Specifically, these include febuastat tablets, lurasidone hydrochloride tablets, and gliclazide tablets. This adjustment will help the company's related products sink into the primary care market, improve drug accessibility, and broaden sales channels. It is not expected to have a significant impact on business performance in the short term, and it will have a positive impact on the company's operating performance in the long term.

Keyuan Pharmaceutical announced that its wholly-owned subsidiary Shandong Linuo Pharmaceutical Co., Ltd. added 4 new products to the “National Essential Drug Catalogue”. Specifically, these include febuastat tablets, lurasidone hydrochloride tablets, and gliclazide tablets. This adjustment will help the company's related products sink into the primary care market, improve drug accessibility, and broaden sales channels. It is not expected to have a significant impact on business performance in the short term, and it will have a positive impact on the company's operating performance in the long term.